Product Reports Resources Pricing Login Book a demo

ARCH Venture Partners

Venture Capital · Founded 1986 · Chicago, United States

#124 Investor Ranking 2026 Top 1% of investors worldwide

Early-stage venture capital for life sciences discoveries

251 Portfolio companies+37% in 5 years
58 Unicorns
18 Decacorns
481 Investments
Jul 2026 Last investment
02 · Biggest holdings

ARCH Venture Partners’ biggest current holdings.

The most valuable companies ARCH Venture Partners still holds, ordered by Dealroom’s latest valuation. Companies that have been acquired or gone public are in Exits instead. Dealroom has no parsed shareholder register for ARCH Venture Partners, so the size of each stake isn’t shown.

#CompanyValuation
  1. 1 PrometheusDecacorn · Robotics · USA $41.0B
  2. 2 Altos LabsUnicorn · Health · USA $6.3B
  3. 3 AledadeUnicorn · Health · USA $3.5B
  4. 4 Xaira TherapeuticsUnicorn · Health · USA $2.7B
  5. 5 ResilienceUnicorn · Health · USA $2.5B
  6. 6 Treeline BiosciencesUnicorn · Health · USA $2.1B
  7. 7 Areteia TherapeuticsUnicorn · Health · USA $1.8B
  8. 8 InsitroUnicorn · Health · USA $1.6B
  9. 9 OratomicUnicorn · Semiconductors · USA $1.5B
  10. 10 SonderMind Wellness CentersUnicorn · Health · USA $1.1B

Unicorns and thoroughbreds ARCH Venture Partners has backed and still holds, at Dealroom’s latest valuation. See the underlying shareholder registers on Dealroom →

03 · Exits

ARCH Venture Partners’ biggest exits.

Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from ARCH Venture Partners’ transaction record.

Thermo Fisher Scientific
IPO · 2014
Entered Series B+Now $258BHealth
IPO · 2000
Entered Series ANow $30BHealth
$114M IPO · 2004
Entered Series B+Now $27BHealth
Array BioPharma
IPO · 2000
Now $11BHealth
IPO · 2019
Entered Series ANow $11BHealth
$3.0B IPO · 2014
Entered Series ANow $9.0BHealth
IPO · 2024
Entered Series ANow $8.0BHealth
$372M IPO · 2018
Entered Series ANow $7.2BHealth
IPO · 2021
Entered Series ANow $6.2BHealth
Scholar Rock
$350M IPO · 2018
Entered Series ANow $6.2BHealth
IPO · 2016
Entered Series ANow $5.7BSemiconductors
$275M IPO · 2025
Entered Series ANow $4.9BHealth
04 · Portfolio analysis

Where ARCH Venture Partners’ portfolio is concentrated.

Distribution of portfolio companies by headquarters country, sector, entry stage and current growth stage. Across all 251 portfolio companies. "Stage entered" is the first priced round the investor joined, derived from the investor’s transaction history.

By countryCount
  1. USA327
  2. China12
  3. UK5
  4. Ireland3
  5. Cuba2
  6. Germany2
  7. Israel2
  8. Singapore2
  9. Sweden2
  10. Canada1
  11. Denmark1
  12. Iceland1
By sectorCount
  1. Health268
  2. Semiconductors20
  3. Enterprise Software17
  4. Energy12
  5. Media10
  6. Food7
  7. Education3
  8. Fashion3
  9. Fintech3
  10. Home Living3
  11. Robotics3
  12. Security3
By stage enteredCount
  1. Series A149
  2. Series B+75
  3. Seed23
By growth stageCount
  1. Late Growth147
  2. Breakout Stage107
  3. Early Growth90
  4. Mature21
05 · Portfolio market map

Inside ARCH Venture Partners’ portfolio.

The 60 highest-funded portfolio companies, of 251 tracked.

Prometheus
Robotics · Decacorn
$41B
Intel Corporation
Semiconductors · Centicorn
$534B
Pfizer
Health · Centicorn
$204B
Altos Labs
Health · Unicorn
$6.3B
Resilience
Health · Unicorn
$2.5B
EQRx
Health
GRAIL
Health · Unicorn
$8.0B
Treeline Biosciences
Health · Unicorn
$2.1B
Xaira Therapeutics
Health · Unicorn
$2.7B
Parabilis Medicines
Health · Unicorn
$4.8B
Sana Biotechnology
Health
$954M
Generate Biomedicines
Health · Unicorn
$2.0B
Aledade
Health · Unicorn
$3.5B
Gossamer Bio
Health
$191M
Vir Biotechnology
Health · Unicorn
$1.1B
Mirador Therapeutics
Health · Unicorn
$2.0B
Maze Therapeutics
Health
$140M
Insitro
Health · Unicorn
$1.6B
ArsenalBio
Health · Unicorn
$1.3B
Neumora Therapeutics
Health
$206M
Kardigan
Health · Unicorn
$1.6B
Lyell Immunopharma
Health
$194M
Metsera
Health · Unicorn
$4.9B
LifeMine Therapeutics
Health
$752M
EGenesis
Health
$764M
Genuity Science
Health
$100M
Ollin Biosciences
Health · Unicorn
$1.3B
Areteia Therapeutics
Health · Unicorn
$1.8B
Brii Biosciences
Health
$415M
CStone Pharmaceuticals
Health
$932M
Sapphire Energy
Energy
Vividion Therapeutics
Health · Unicorn
$1.5B
Verve Therapeutics
Health
$566M
Merck & Co.
Health · Centicorn
$361B
Be Bio
Health
$650M
Aspen Neuroscience
Health
$738M
Denali Therapeutics
Health · Unicorn
$1.5B
Erasca
Health · Unicorn
$6.2B
Ikaria
Health · Unicorn
$2.3B
Prime Medicine
Health
$615M
Sonoma Biotherapeutics
Health · Unicorn
$1.1B
Synchron
Health
$900M
Seaport Therapeutics
Health
$989M
Juno Therapeutics
Health · Unicorn
$9.0B
Tome Biosciences
Health
$512M
Arbor Biotechnologies
Health · Unicorn
$1.1B
Sironax
Health
$800M
Oratomic
Semiconductors · Unicorn
$1.5B
Dewpoint Therapeutics
Health
$600M
Paradigm
Health · Unicorn
$1.0B
Orbital Therapeutics
Health · Unicorn
$1.5B
Chroma Medicine
Health
$540M
CREATE Medicines
Health
$488M
Syros Pharmaceuticals
Health
$1.9M
AgBiome
Food
$464M
Boundless Bio
Health
Rapport Therapeutics
Health · Unicorn
$1.8B
AIRNA
Health
$620M
Rubius Therapeutics
Health
Twist Bioscience
Health · Unicorn
$7.2B
06 · Portfolio founders

Where ARCH Venture Partners’ portfolio founders come from.

178 founders across the 100 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.

LocationCount
  1. United States164
  2. United Kingdom3
  3. China2
  4. Australia1
  5. France1
  6. India1
  7. Portugal1
UniversityCount
  1. Massachusetts Institute of Technology18
  2. Harvard University15
  3. Stanford University8
  4. Harvard Medical School7
  5. Harvard Business School5
  6. University of California, Berkeley5
  7. Yale University4
  8. Columbia University3
  9. Duke University3
  10. Northwestern University3
Previous companyCount
  1. Genentech5
  2. Massachusetts Institute of Technology5
  3. Merck & Co.5
  4. Stanford University5
  5. Biogen4
  6. Broad Institute4
  7. Harvard Medical School4
  8. Massachusetts General Hospital4
  9. MyoKardia4
  10. Novartis4